Arctic Bioscience - Regulatory Filings 2025

Arctic Bioscience - HeROPA 1-year read-out: Top-line results expected within 2-3 weeks

All patients have completed 1 year of treatment and the HeROPA phase 2b clinical

trial on HRO350 in mild-to-moderate psoriasis is completed. Top-line results

were planned to be announced by end of Q1 2025, however cleaning of the

comprehensive dataset from more than 500 patients for 1 year of treatment is

taking more time than anticipated. The top-line data are currently being cleaned

and quality controlled. Top-line results are expected to be published within 2-3

weeks.

Analyses on all endpoints will then be presented in the full clinical study

report in May this year.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

AI assistant